MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

Plain-language summary

Published 2023 in J Gerontol A Biol Sci Med Sci, this work by Pencina KM and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

• Clinical pharmacology study of MIB-626, an oral beta-NMN formulation, in middle-aged and older adults
• Showed increases in circulating NAD+ and NAD+ metabolome measures after oral administration
• Useful for pharmacokinetic context, not proof of disease treatment or longevity benefit

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions, with secondary relevance to dosage and safety. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.